北陆药业
(300016)
| 流通市值：50.25亿 | | | 总市值：50.32亿 |
| 流通股本：5.62亿 | | | 总股本：5.63亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 872,684,962.37 | 584,208,873.71 | 282,680,687.56 | 983,554,462.55 |
| 营业收入 | 872,684,962.37 | 584,208,873.71 | 282,680,687.56 | 983,554,462.55 |
| 二、营业总成本 | 839,914,027.39 | 553,854,245.81 | 270,747,397.37 | 980,948,906.19 |
| 营业成本 | 472,361,615.01 | 309,243,894.14 | 154,191,274.58 | 514,658,184.71 |
| 税金及附加 | 11,210,241.99 | 7,597,441.8 | 3,650,421.65 | 12,927,131.99 |
| 销售费用 | 191,274,741 | 128,352,971.62 | 56,669,317.32 | 243,347,360.61 |
| 管理费用 | 65,518,907.81 | 43,660,638.96 | 21,021,513.46 | 88,864,434.71 |
| 研发费用 | 63,963,081.76 | 39,027,284.47 | 21,400,376.2 | 69,238,085.8 |
| 财务费用 | 35,585,439.82 | 25,972,014.82 | 13,814,494.16 | 51,913,708.37 |
| 其中:利息费用 | 37,194,306.43 | 27,537,146.77 | 15,135,666.42 | 58,006,849.73 |
| 其中:利息收入 | 3,165,047.24 | 2,110,189.04 | 1,785,843.99 | 5,376,249.14 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,239,359.21 | -855,712.62 | 89,000.21 | -11,947,472.65 |
| 加:投资收益 | 6,744,921.07 | 990,763.49 | 1,940,075.2 | 7,358,221.99 |
| 资产处置收益 | -1,266,134.62 | -1,266,134.62 | -1,269,354.01 | 122,937.98 |
| 资产减值损失(新) | -4,889,852.17 | -2,499,339.52 | -813,005.1 | -9,929,441.71 |
| 信用减值损失(新) | -2,181,030.03 | -1,762,345.3 | 963,459.86 | 664,247.84 |
| 其他收益 | 9,399,488.38 | 5,573,917.52 | 2,818,198.99 | 10,530,122.3 |
| 四、营业利润 | 45,817,686.82 | 30,535,776.85 | 15,661,665.34 | -595,827.89 |
| 加:营业外收入 | 447,819.13 | 389,948.31 | 152,189.02 | 1,637,862.01 |
| 减:营业外支出 | 1,280,945.32 | 874,294.37 | 187,517.13 | 1,825,917.85 |
| 五、利润总额 | 44,984,560.63 | 30,051,430.79 | 15,626,337.23 | -783,883.73 |
| 减:所得税费用 | 5,518,574.84 | 3,114,209.89 | 2,324,017.11 | -1,051,535.54 |
| 六、净利润 | 39,465,985.79 | 26,937,220.9 | 13,302,320.12 | 267,651.81 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 39,465,985.79 | 26,937,220.9 | 13,302,320.12 | 267,651.81 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 44,176,899.13 | 29,966,924.99 | 14,538,525.05 | 13,651,677.43 |
| 少数股东损益 | -4,710,913.34 | -3,029,704.09 | -1,236,204.93 | -13,384,025.62 |
| 扣除非经常损益后的净利润 | 33,675,826.98 | 29,737,612.39 | 13,087,958.97 | 14,094,405.96 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.06 | 0.03 | 0.03 |
| (二)稀释每股收益 | - | 0.09 | 0.05 | 0.09 |
| 九、综合收益总额 | 39,465,985.79 | 26,937,220.9 | 13,302,320.12 | 267,651.81 |
| 归属于母公司股东的综合收益总额 | 44,176,899.13 | 29,966,924.99 | 14,538,525.05 | 13,651,677.43 |
| 归属于少数股东的综合收益总额 | -4,710,913.34 | -3,029,704.09 | -1,236,204.93 | -13,384,025.62 |
| 公告日期 | 2025-10-29 | 2025-08-26 | 2025-04-25 | 2025-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |